StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays cut their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Price Performance

CLLS opened at $1.87 on Thursday. The firm has a market cap of $103.93 million, a P/E ratio of -1.44 and a beta of 3.10. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. Cellectis has a fifty-two week low of $1.70 and a fifty-two week high of $3.77. The firm has a 50-day moving average of $1.97 and a 200 day moving average of $2.20.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the previous year, the business earned ($0.31) EPS. On average, research analysts expect that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Long Focus Capital Management LLC boosted its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the period. First Affirmative Financial Network bought a new stake in shares of Cellectis during the third quarter valued at about $45,000. XTX Topco Ltd purchased a new stake in shares of Cellectis in the second quarter worth about $29,000. Finally, Principal Financial Group Inc. boosted its position in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares during the period. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.